Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI). (SCD-PED-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02820350
Recruitment Status : Recruiting
First Posted : June 30, 2016
Last Update Posted : August 20, 2018
Sponsor:
Collaborators:
Innovative BioTherapies (IBT)
Children's Hospital Medical Center, Cincinnati
Information provided by (Responsible Party):
CytoPherx, Inc

Brief Summary:
The SCD (Selective Cytopheretic Device) is an extracorporeal device used as an adjunct to renal replacement therapy (RRT) to improve the outcomes of pediatric patients with acute kidney injury (AKI). Funding Source - FDA OOPD (SCD-PED-01)

Condition or disease Intervention/treatment Phase
Acute Kidney Injury Device: SCD-F40 Phase 2

Detailed Description:
The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to commercially available Continuous Renal Replacement Therapy (CRRT) devices. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and it is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI)
Study Start Date : October 2016
Actual Primary Completion Date : July 2018
Estimated Study Completion Date : March 31, 2020

Intervention Details:
  • Device: SCD-F40
    CRRT with SCD
    Other Name: Selective Cytopheretic Device (SCD)


Primary Outcome Measures :
  1. Primary Objective: Adverse events related to treatment occurring during and 60 days post treatment initiation. [ Time Frame: 60 days ]
    The primary clinical endpoint in this trial is safety of SCD treatment after up to seven consecutive 24 hour therapy sessions. Safety as determined with adverse events related to treatment up to 60 days following treatment initiation.


Secondary Outcome Measures :
  1. The effect of SCD treatment on all cause mortality through 60 days post-randomization. [ Time Frame: Day 60 following treatment end ]
    The effect of SCD treatment on all cause mortality through 60 days post-randomization.

  2. The effect of SCD treatment on Renal Replacement Therapy dependency at day 60. [ Time Frame: Day 60 following treatment end ]
    RRT dependency at day 60 is defined as patient not receiving any form of intermittent or continuous renal replacement therapy at 60 days post enrollment in the study with no plans for additional intermittent or continuous renal replacement therapy.

  3. Mortality at day 28 [ Time Frame: Day 28 following treatment ]
    Mortality at day 28 following treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 22 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A patient, or legal representative, has signed a written informed consent form.
  2. Must be receiving medical care in an intensive care unit (e.g., ICU, MICU, SICU, CTICU, Trauma).
  3. Age less than 22 years.
  4. Females of child bearing potential who are not pregnant (confirmed by a negative serum pregnancy test) and not lactating if recently post-partum.
  5. Intent to deliver full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours.
  6. Clinical diagnosis of AKI due to etiologies requiring CRRT (see Appendix B). AKI is defined as acute kidney injury with any one of the following:

    • Increase in SCr by ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours or;
    • Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days or;
    • Urine volume <0.5ml/kg/h for 6 hours
  7. At least one non-renal organ failure (defined as receiving mechanical ventilation or at least one vasoactive medication to treat hypotension) OR presence (proven or suspected) of sepsis. (Appendix C).

Exclusion Criteria:

  1. Threshold blood pressure of 80/40 mmHg-- patients with both a systolic blood pressure of less than 80 mmHg and a diastolic blood pressure of less than 40 mmHg.
  2. Irreversible brain damage based on available historical and clinical information.
  3. Patients with a solid organ transplant or those with a bone marrow or stem cell transplant in the previous 100 days or who have not engrafted.
  4. Acute or chronic use of circulatory support device other than ECMO such as LVADs, RVADs, BIVADs.
  5. Presence of preexisting advanced chronic renal failure (i.e., ESRD) requiring chronic renal replacement therapy prior to this episode of acute kidney injury or with pre-existing chronic kidney disease (CKD) defined as a eGFR<30ml/min/1.73m2. Patients who have never seen a pediatric nephrologist will be assumed not to have pre-existing CKD.
  6. AKI occurring in the setting of burns, obstructive uropathy, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, cyclosporine, or tacrolimus nephrotoxicity.
  7. Received >12 hour of CRRT (not including SCUF on ECMO) during this hospital admission or prior to transfer from an outside hospital.
  8. Received >1 hemodialysis treatment during this hospital admission or prior to transfer from an outside hospital.
  9. Metastatic malignancy which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three month period after study therapy.
  10. Chronic immunosuppression with the exception of corticosteroids up to a dose of 10mg per day.
  11. HIV or AIDS.
  12. Severe chronic liver failure as determined by standard diagnostic requirements.
  13. Current Do Not Attempt Resuscitation (DNAR), Allow Natural Death (AND), or withdrawal of care status, or anticipated change in status within the next 7 days.
  14. Patient not expected to survive 28 days because of an irreversible medical condition. (This is not restrictive to AKI, and may include situations such as the presence of irreversible brain damage, untreatable malignancy, inoperable life threatening condition, or any condition to which therapy is regarded as futile by the PI.)
  15. Any medical condition that the Investigator thinks may interfere with the study objectives.
  16. Physician refusal.
  17. Dry weight of <15 kg.
  18. Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical trials where only measurements and/or samples are taken (NO TEST DEVICE OR TEST DRUG USED) are allowed to participate.
  19. Use of any other Investigational drug or device within the previous 30 days. -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02820350


Contacts
Layout table for location contacts
Contact: H. David Humes, MD 734-417-6825 dhumes@cytopherx.com
Contact: Stuart Goldstein, MD 513-803-3295 Stuart.Goldstein@cchmc.org

Locations
Layout table for location information
United States, Alabama
Children's Hospital of Alabama Recruiting
Birmingham, Alabama, United States, 35233
Contact: Lynn Dill, RN    205-638-9347    ldill@peds.uab.edu   
United States, Georgia
Children's Healthcare of Atlanta at Egleston Recruiting
Atlanta, Georgia, United States, 30322
Contact: Cheryl Stone, RN    404-785-6454    CherylL.Stone@choa.org   
United States, Iowa
University of Iowa Children's Hospital Withdrawn
Iowa City, Iowa, United States, 52242
United States, Michigan
CS Mott Children's Hospital Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Barb Smith    734-232-5401    barsmith@med.umich.edu   
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Theresa Mottes    513-803-3296    theresa.mottes@cchmc.org   
Sponsors and Collaborators
CytoPherx, Inc
Innovative BioTherapies (IBT)
Children's Hospital Medical Center, Cincinnati

Layout table for additonal information
Responsible Party: CytoPherx, Inc
ClinicalTrials.gov Identifier: NCT02820350     History of Changes
Other Study ID Numbers: SCD-PED-01
FD005092-01 ( Other Grant/Funding Number: FDA OOPD )
First Posted: June 30, 2016    Key Record Dates
Last Update Posted: August 20, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by CytoPherx, Inc:
Acute Renal Failure
Acute kidney injury
Continuous Renal Replacement Therapy
Selective cytopheretic device
Pediatric
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Wounds and Injuries
Renal Insufficiency
Kidney Diseases
Urologic Diseases